Asset
EFZOFITIMOD
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05415137 | phase3 | completed | 2022-09-15 | 2025-06-25 | aTyr Pharma, Inc. | Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis |
| NCT03824392 | phase1_2 | completed | 2019-01-29 | 2021-06-29 | aTyr Pharma, Inc. | Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis |
| NCT05892614 | phase2 | recruiting | 2023-10-26 | 2026-04-01 | aTyr Pharma, Inc. | Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD) |
| NCT04412668 | phase2 | completed | 2020-06-04 | 2020-10-23 | aTyr Pharma, Inc. | Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19 |
FDA applications (0)
This company has no applications containing this asset.